A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Trial Status: Recruiting
Start Date: September, 2018
Expected Enrolment: 500
Type of Trial: Treatment
Protocol IDs: NCT03653507, 8951-CL-0302, 2018-000519-26
Trial Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Masking: Double (Participant, Investigator)
Trial Phase: Phase 3
Medical Conditions: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
  • oxaliplatin
  • capecitabine
  • placebo
  • zolbetuximab
Lead Sponsor: Astellas Pharma Global Development, Inc.
Sponsors/Study Groups: None specified
Type of Treatment: None specified
Principal Investigator(s): Medical Director, Astellas Pharma Global Development
Date posted on clinicaltrials.gov: August 24, 2018
Last updated: April 23, 2021
This trial was imported from ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society